Schaper Benz & Wise Investment Counsel Inc. WI Has $11.74 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Schaper Benz & Wise Investment Counsel Inc. has increased its holdings in Regeneron Pharmaceuticals by 11.2%, owning 22,357 shares valued at approximately $11.74 million.
• Wall Street analysts remain positive on Regeneron's outlook, with a consensus price target of $817.88 and a majority rating of "Moderate Buy".
• Regeneron recently reported an earnings per share of $12.89 for its last quarter, significantly exceeding analysts' estimates, indicating strong financial performance.

Schaper Benz & Wise Investment Counsel Inc. WI increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,357 shares of the biopharmaceutical company's stock after buying an additional 2,259 shares during the quarter. Schaper Benz & Wise Investment Counsel Inc. WI's holdings in Regeneron Pharmaceuticals were worth $11,737,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, SouthState Corp raised its stake in shares of Regeneron Pharmaceuticals by 550.0% in the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 44 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a research note on Friday, October 10th. Finally, Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $817.88.

Regeneron Pharmaceuticals Trading Up 0.9%

Regeneron Pharmaceuticals stock opened at $584.74 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $959.60. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a market capitalization of $61.98 billion, a P/E ratio of 14.74, a PEG ratio of 1.81 and a beta of 0.31. The stock has a 50-day simple moving average of $576.17 and a 200 day simple moving average of $562.42.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the previous year, the company posted $11.56 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.